Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro.
D000276:Adjuvants, Immunologic / Q000302:isolation & purification / Q000494:pharmacology*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D048691:Grifola / Q000737:chemistry*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D051379:Mice; D013778:Tetrazolium Salts; D047071:beta-Glucans / Q000302:isolation & purification / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D013778:Tetrazolium Salts; D047071:beta-Glucans; C059087:2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxide; C064197:beta-1,6-glucan; D004317:Doxorubicin; C033363:beta-1,3-glucan